MolDX: Minimal Residual Disease Testing for Cancer

This contractor provides limited coverage for MRD testing (PCR or sequencing) in patients with a personal history of cancer when the test is used in the analytically validated population and intended use, has peer‑reviewed evidence of clinical validity (and, where applicable, clinical utility), and when detection would change management per NCCN or other established guidelines. NGS‑based tests must meet NCD 90.2 conditions when applicable and non‑FDA single‑gene or sequencing tests must complete a technical assessment demonstrating analytical validity, clinical validity, and clinical utility; testing frequency and schedules follow national or society guidelines.

"MRD testing is covered for patients with a personal history of cancer when the cancer type and stage are within the test's intended use."

Sign up to see full coverage criteria, indications, and limitations.